Market Access Views & Analysis

Views & Analysis

Market Access

The changing landscape of drug clinical assessment: Tommy Br...

In a new pharmaphorum podcast, Tommy Bramley, SVP of market access and healthcare consulting at Cencora, discusses Joint Clinical Assessments.

Market Access

BIO 2025: Makary: Drugs don’t have to take 10 years to get t...

FDA Commissioner Dr Martin Makary took the stage at BIO 2025 to detail the way he and his team have been challenging “deeply held assumptions”.

Market Access

Political uncertainties, tariffs, funding crunch? LSX World ...

The weather was hot in London for this year’s LSX World Congress – but what was the atmosphere like at Europe’s leading partnering, strategy, and investment event?

Market Access

Is money the only metric that really matters in UK’s VPAG? I...

The UK’s Voluntary Scheme that covers pricing, access, and growth of branded medicines has been generating a lot of attention lately.

Market Access

VCs upbeat about European life sciences market, despite unce...

It has been a curious start to the year for pharma and biotech investment.

Market Access

pharmaphorum podcast Episode 179a - Cen Zorlular, Er-Kim Pharmaceuticals

EAPs: Market access outside of the US and Western Europe

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Cem Zorlular, CEO of Er-Kim Pharmaceuticals about early access programmes.

The changing landscape of drug clinical assessment: Tommy Br...

BIO 2025: Makary: Drugs don’t have to take 10 years to get t...

Political uncertainties, tariffs, funding crunch? LSX World ...

Is money the only metric that really matters in UK’s VPAG? I...

VCs upbeat about European life sciences market, despite unce...

EAPs: Market access outside of the US and Western Europe

LSX2026: On a therapeutic vision for ocular disease, with Al...

Using AI-driven synthetic personas to take your insights fur...

Views & Analysis

Editor's Picks